PT  - JOURNAL ARTICLE
AU  - Park, Hailey J.
AU  - Tan, Sophia T.
AU  - León, Tomás M.
AU  - Jain, Seema
AU  - Schechter, Robert
AU  - Lo, Nathan C.
TI  - Predicting the public health impact of bivalent vaccines and nirmatrelvir-ritonavir against COVID-19
AID  - 10.1101/2023.05.18.23289533
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.05.18.23289533
4099  - http://medrxiv.org/content/early/2023/05/21/2023.05.18.23289533.short
4100  - http://medrxiv.org/content/early/2023/05/21/2023.05.18.23289533.full
AB  - Background Uptake of COVID-19 bivalent vaccines and oral medication nirmatrelvir-ritonavir (Paxlovid) has remained low across the United States. Assessing the public health impact of increasing uptake of these interventions in key risk groups can guide further public health resources and policy.Methods This modeling study used person-level data from the California Department of Public Health on COVID-19 cases, hospitalizations, deaths, and vaccine administration from July 23, 2022 to January 23, 2023. We modeled the impact of additional uptake of bivalent COVID-19 vaccines and nirmatrelvir-ritonavir during acute illness in different risk groups defined by age (50+, 65+, 75+ years) and vaccination status (everyone, primary series only, previously vaccinated). We predicted the number of averted COVID-19 cases, hospitalizations, and deaths and number needed to treat (NNT).Results For both bivalent vaccines and nirmatrelvir-ritonavir, the most efficient strategy (based on NNT) for averting severe COVID-19 was targeting the 75+ years group. We predicted that perfect coverage of bivalent boosters in the 75+ years group would avert 3,920 hospitalizations (95%UI: 2,491-4,882; 7.8% total averted; NNT 387) and 1,074 deaths (95%UI: 774-1,355; 16.2% total averted; NNT 1,410). Perfect uptake of nirmatrelvir-ritonavir in the 75+ years group would avert 5,644 hospitalizations (95%UI: 3,947-6,826; 11.2% total averted; NNT 11) and 1,669 deaths (95%UI: 1,053-2,038; 25.2% total averted; NNT 35).Conclusions These findings suggest prioritizing uptake of bivalent boosters and nirmatrelvir-ritonavir among the oldest age groups would be efficient and have substantial public health impact in reducing the burden of severe COVID-19, but would not address the entire burden of severe COVID-19.Competing Interest StatementDrs. Leon, Jain, and Schechter are employees of CDPH and were involved in the analysis and interpretation of the data and the review and approval of the manuscript.Funding StatementThis study is supported by funding from the California Department of Public Health. NCL is supported by the National Institutes of Health, NIAID New Innovator Award (DP2 AI170485).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board at the University of California, San Francisco. The requirement for informed consent was waived given the analysis used anonymized secondary datasets that were collected as part of public health surveillance and deemed minimal risk.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://github.com/hailey-park/bivalent-vaccines-paxlovid-impacts